TAVR(TAVI in Europe)vs. SAVR — Cardiologists, heart surgeons sound alarm over widespread use of TAVR in low-risk patients
TAVR(TAVI in Europe)vs. SAVR —
Cardiologists, heart surgeons sound alarm over widespread use of TAVR in low-risk patients
Source: Medical Commentary – October 4, 2025, from JACC & ACC report
Keynotes :
1-Background
• Both TAVR (Transcatheter Aortic Valve Replacement) and SAVR (Surgical Aortic Valve Replacement) treat severe aortic stenosis.
• TAVR use has grown rapidly — even in low-risk and younger patients (<65 years) — raising questions about long-term durability.
2-Survival and Recovery
(First 5 Years):
• Survival is almost identical ≈ 70–75 % TAVR
(vs ≈ 70–75 % SAVR)
• Recovery is faster after TAVR
(short hospital stay TAVR vs longer SAVR)
• Bleeding is lower ≈ 5 % TAVR
(vs ≈ 10–15 % SAVR)
• Atrial fibrillation is much less common in TAVR ≈ 5 %
(vs ≈ 30 % SAVR)
• After a few months, doctors start to see some specific TAVR-related issues.
3-TAVR-Specific Complications
• Pacemaker rate: ≈ 20 % TAVR (vs ≈ 5 % SAVR):-
• Main timing: within first 3–7 days post-TAVR
• Most (≈ 85 %) during index hospitalization
• Few (≈ 10–15 %) within first 30 days
• Very rare (< 2 %) after 1 month
• Paravalvular leak (PVL) ≈ 20 % TAVR
(vs ≈ 3 % SAVR)
• Stroke rate is slightly lower or similar with TAVR (≈2–3% TAVR vs ≈3–4% SAVR), especially with newer-generation valve systems..
• Major bleeding ≈ 5 % TAVR
(vs ≈ 10–15 % SAVR)
• Early hospital mortality ≈ 1–2 % TAVR
(vs ≈ 2–3 % SAVR)
4-Medium- and Long-Term Course (5–10 Years)
• From year 2 to 5, valve function stays good, but some patients start to see thickened leaflets or rising gradients ≈ 10 % TAVR
(vs ≈ 5 % SAVR)
• After ≈ 10 years, redo procedures may be needed in ≈ 15–20 % TAVR
(vs ≈ 10–15 % SAVR)
• Durability averages ≈10 years for TAVR (vs ≈10–15 years for SAVR using bioprosthetic valves, while mechanical valves may last >20 years — overall, surgical valve replacement remains more durable).
• Full 10-year data from PARTNER 3 and Evolut Low Risk are expected around 2030.
5-Surgical (SAVR) Profile
• Invasiveness: higher (open-chest operation).
• Pacemaker need ≈ 5 % SAVR
(vs ≈ 20 % TAVR)
• Leak around valve ≈ 3 % SAVR
(vs ≈ 20 % TAVR)
• Atrial fibrillation ≈ 30 % SAVR
(vs ≈ 5 % TAVR)
• Major bleeding ≈ 10–15 % SAVR
(vs ≈ 5 % TAVR)
• Durability ≈ 10–15 years SAVR
(vs ≈ 8–10 years TAVR)
• Redo need ≈ 10–15 % by 15 yrs SAVR
(vs ≈ 15–20 % by 10 yrs TAVR)
6-Patient Counseling
• TAVR: easier, faster, and ideal for older / high-risk patients.
• SAVR: longer recovery but stronger and more durable for younger / low-risk patients.
• The heart team should clearly explain short-term comfort (TAVR) versus long-term durability (SAVR) before any decision.
7-Main Differences Summary:
• Survival is the same ≈ 70–75 % TAVR
(vs ≈ 70–75 % SAVR)
• Pacemaker need is higher ≈ 20 % TAVR
(vs ≈ 5 % SAVR)
• Leak around valve is higher ≈ 20 % TAVR
(vs ≈ 3 % SAVR)
• Atrial fibrillation is lower ≈ 5 % TAVR
(vs ≈ 30 % SAVR)
• Bleeding is lower ≈ 5 % TAVR
(vs ≈ 10–15 % SAVR)
• Durability shorter ≈ 8–10 yrs TAVR
(vs ≈ 10–15 yrs SAVR)
• Redo procedure more common ≈ 15–20 % TAVR
(vs ≈ 10–15 % SAVR)
